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Introduction 
Leukaemias comprise approximately 8% of the entire 
human  cancers,  and  around  half  of  these  cases  are 
classified  as  acute  leukemia.  Acute  myelogenous 
leukemia  (AML)  increase  the  proliferation  in 
megakaryocytic,  monocytic,  granulocytic,  and 
erythrocytic  lineages.
1  AML  is  a  heterogeneous 
disease,  which  shows  a  high  variety  of  phenotypes. 
Immunophenotyping  is  crucial  for  diagnosis  and  for 
deﬁnition of particular AML subtypes.
2 Acute leukemia 
involves both children (ALL) and adults (AML) with a 
prevalence rate of approximately 4 million people per 
year  in  the  developed  countries.
1  Morphology  and 
Immunohistochemistry are not such reliable method for 
leukemia  diagnosis  and  classification;  hence, 
Immunophenotyping become a widely used method to 
diagnose  and  classify  acute  leukemias,  first  in 
distinction  of  acute  leukemia  from  other  neoplastic 
diseases and reactive disorders, second in distinction of 
AML and ALL and third, in classification of AML and 
ALL  into  their  subsets.
3  More  than  95%  of  acute 
myelogenous  leukemia  cases  (AML)  cases  can  be 
easily  distinguished  from  ALL  by  surface  antigen 
analysis. 
Immunophenotype as well as a variety of clinical and 
biological  parameters  examined  for  potential 
importance  in  predicting  treatment  response  and 
patient's survival. 
4 When the morphology interpretatin 
is  difficult,  immunotyping  can  be  extremely  helpful. 
The  main  benefit  of  using  surface  antigens  by 
flowcytometry  is  the  identification  of  particular 
leukemia  subtype  that  cannot  be  recognized  by 
morphological  criteria.  Although  Immunotyping  of 
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CD2 in 58.35 of M1cases, 21.40% of M2 cases, 33.3 of M3 and 20% of M5; but M4 
patients  lacked  this  marker.  The  CBC  analysis  demonstrated  a  wide  range  of 
haemoglobin  concentration,  Platelet  and  WBC  count  which  varied  from  normal  to 
anaemia, thrombocytopenia to thrombocytosis and leukopenia to hyper leukocytosis.  
Conclusions: Our findings showed that CD7 and CD2 were the most common aberrant 
marker  in  Iranian  patients  with  AML.  However,  we  are  not  find  any  significant 
correlation between aberrant phenotype changing and MRD in our population. Taken 
together,  this  findings  help  to  provide  new  insights  in  to  the  investigation  of  other 
aberrant phenotypes that may play roles in diagnosis and therapeutic of AML.  
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peripheral blood (PB) and bone marrow (BM) is not 
decision making for an exact therapeutic procedure by 
itself, is a practical prognostic indicator.
5 The diagnosis 
and management of acute leukemia mainly depend on 
the  detection,  identification  and  characterization  of 
leukemic  cells.
6  Some  studies  show  a  strong  relation 
between  particular  immunophenotypes  and  genetic 
recurrent.
7  Although  many  acute  leukaemias  can  be 
correctly  identified  morphologically  or  by 
immunohistocytochemical  analysis, 
immunophenotyping  is  still  essential  for  accurate 
identification of some subtypes of AML such as  M0, 
M1 and M7.  
Aberrant  phenotype  is  a  phenomenon  in  which 
lymphoid-associated  and  other  myeloid  lineage 
markers  expressed  in  myeloblasts  or  myeloid-
associated  markers  expressed  in  lymphoblasts. 
Aberrant  phenotype  incidence  has  been  reported  in 
both ALL and AML with varying frequencies as high 
as 88%.
8,9 Up to 48% of AML cases were reported to 
have aberrant expression of a single antigen associated 
with  lymphoid  cell  lineage.
8-11  The  incidence  of  the 
aberrant phenotypes in AML is still controversial and 
different results have been found by different groups, 
probably because of the several reasons including, use 
of  a  large  variety  of  monoclonal  antibody  (MoAbs) 
panels, use of different reagents against the CD surface 
antigens,  different  cut-off  levels,  analysis  of  fresh  or 
frozen  cell  material,  and  most  importantly  the 
difference between phenotypic characteristics of blast 
cells  of  children  and  adults  patient.
12,13  Currently, 
Flowcytometeric  analysis  of  leukemic  blasts  has 
become  significant  also  for  classification  of 
biphenotypic  and  bilineal  acute  leukemias  too. 
Recently, although  the  prognostic value  of  individual 
antigen  expressions  on  leukemic  cells  is  still 
controversial, detection of minimal residual disease by 
flowcytometery,  especially  in  AML,  and  monitoring 
the  acute  leukemia  patients  who  go  into  remission 
become exceedingly important.
14  
Several  investigators  use  dual/multi-color 
ﬂowcytometric  immunophenotyping  to  identify 
aberrant phenotype. This allows simultaneous analysis 
of two light scatter and up to four fluorescence signals. 
Multiparameter  high-resolution  flow  cytometry  has 
been  developed  to  precisely  identify  lineage 
characteristics of leukemia.
6,7 
The aim of this study is to evaluate the incidence of 
aberrant  phenotypes  and  possible  prognostic  value  in 
peripheral and bone marrow blood mononuclear cells 
of Iranian patients with AML. 
 
Materials and Methods 
Patient selection  
56  new  cases  of  adult  AML,  who  admitted  and 
diagnosed from 2010 to 2012 in Shahid Ghazi hospital 
(Tabriz,  Iran).  AML  confirmed  by  bone  marrow 
aspiration  sample  and  peripheral  blood  smear  (PBS) 
based  on  the  morphology  and  immune  phenotyping. 
All cases were characterized according to the French – 
American –British (FAB) cooperative group based on 
morphological  criteria  and  classified  as  follows:  M0 
(3), M1 (12), M2 (16), M3 (11), M4 (8), M5 (5), M7 
(1). 
 
Immunophenothyping 
Bone Marrow Samples 
Bone  marrow  Samples  were  aspirated  from  the  iliac 
crest.  The  specimens  were  collected  by  expert 
oncologist and drawn into EDTA tube. 
 
Peripheral blood samples 
The patients WBC count was adjusted at less than 10x 
10³/ml. Each sample had  more than mentioned  count 
was diluted in order to reach the appropriate count. A 
specimen  which  contained  any  clout  is  excluded.  A 
peripheral blood smear was prepared for microscopic 
assessment. 
 
Bone marrow analysis 
A  bone  marrow  smear  was  prepared  for  microscopic 
examination.  Bone  marrow  aspirate  was  checked  for 
clot existence, if any was present, it was disintegrated 
with  wooden  sticks.  In  order  to  remove  any  fat  or 
proteins, the bone marrow sample was washed before 
the  procedure.  Washing  instruction  steps  are:  adding 
about 4-5 ml of 2% PBS to 1.5 -2 ml of bone marrow 
aspirate in test tube, 10 minutes centrifuge at 2500 rpm 
(sigma.  USA),  removing  the  supernatant  and 
resuspending pellet with adequate volume of 2%PBS. 
These steps repeated two times. After washing process 
done, cell counting was performed by CBC Analyzer or 
hemacytometer. 
 
Flow Cytometric Analysis of Acute Leukemia Cases 
Lysing  and  Staining:  Ten  microliters  of  fluoresceine 
isothiocyanate  (FITC)  conjugated  monoclonal 
antibody,  10μl  of  Phycoerythrin  (PE)  conjugated 
monoclonal  antibody,  5μl  of  Allophycocyanin  (APC) 
conjugated monoclonal antibody, and 5μl of Peridinin-
chlorophyll  protein  complex  (perCP)  conjugated 
monoclonal antibody was added to 12 *75-mm tubes, 
afterward 100μL of whole blood was in each tube. The 
mixture was Vortexed tenderly and incubated about 45 
minutes to 1 hour in the dark area at room temperature 
(20-  25˚C).  Tow  ml  of  1X  FACS  lysing  buffer  was 
added  to  incubated  mixture.  Then  it  was  vortexed 
tenderly and incubated for 20 minutes in the dark area 
at room temperature again; after that Centrifuge at 500g 
for 5 minutes was done. The supernatant was removed. 
Subsequently 2-3 ml of washing buffer was added and 
centrifuged at 500g for 5 minutes and the supernatant 
was removed. 1 ml of 1% cell fix (paraformaldehyde 
solution)  was  added  and  mixed  completely,  analysis 
can be done immediately or fixed cells can be stored at 
2-8˚C  until  analysing  them.  Analysis  was  done  by 
FACS  brand  flow  cytometer.  Samples  vortexed 
thoroughly prior to acquisition.  
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Flow  Cytometry  Analysis:  The  BD  FACS  Calibur 
(Becton, Dickinson Fluorescence Activated Cell Sorter 
is  a  trademark  of  Becton,  Dickinson  Company,  CA, 
USA) had been used for immunophenotyping analysis. 
The  BD  FACS  Calibur  is  a  dual-laser,  four-color, 
bench-top  and  fully  integrated  multiparameter  system 
that  is  designed  particularly  to  support  a  variety  of 
applications. 
The  appropriate  concentration  for  suspensions 
considered  about  10
6-10
7  cells/ml.  The  analysis  was 
limited to the blast  population, by gating on  forward 
and side light scatter parameters therefore the majority 
of the lymphocytes, monocytes, and granulocytes were 
excluded. Analysis of presentation samples is assisted 
by the high percentage of blasts, but because normal 
hematopoietic  progenitors  also  display  the  surface 
markers  most  commonly  associated  with  AML  (ie, 
CD34,  CD38,  CD33,  CD13,  and  HLA-DR),  the 
analysis  of  remission  samples  (4%  blasts)  is 
problematic, thus they were excluded from our study. 
We  applied  Acute  Leukemia  Panel  with  these 
following  CD  markers:  CD2,  CD3,  CD7,  CD10, 
CD11b,  CD13,  CD14,  CD15,  CD19,  CD20,  CD22, 
CD33, CD34, CD38, CD41, CD45, CD61, GLYCO A, 
CD117, HLA-DR, cy MPO and TdT. 
 
Statistical analysis 
Data were analysed qualitatively and quantitatively by 
means  of  SPSS  14  (Statistical  package  for  social 
sciences 14). Frequency and descriptive analysis were 
used  in  all  statistical  process.  The  statistical 
signiﬁcance value was chosen to be below 0.05. 
 
Results 
Out  of  56  cases  with  AML  33  (58.93%)  cases  were 
male and 23 (41.07%) of them were female. AML is 
more  prevalent  in  men  than  women;  male  to  female 
ratio was 1.5/1.0. Patient’s age ranged between 20 and 
85 (mean+/- SD: 40.7+/- 1.53). Based on patient’s age, 
we  divided  them  into  four  groups:  younger  than  30 
years, from 31 to 50, between 41 and 50 and older than 
50. AML was more prevalent in the fourth group. 
Among different markers, the most positive markers in 
myeloid  lineage  antigens  were  CD38,  CD45  (100%), 
CD13 (92.9), CD33 (90.2%), and MPO (42.3%) as well 
as  hematopoietic  progenitor  cell  surface  antigens 
including  HLA-DR  (72%),  CD117  (78.4%),  CD34 
(52%).  
In  acute  myeloid  leukemia,  we  considered  lymphoid 
antigens  as  aberrant  antigens.  CD7  was  positive  in 
72.7% of cases in M1 and 28.5% in M2 but M3 and 
M4 cases lacked this marker. We detected CD2, T-cell 
marker, in 58.35 of M1cases, 21.40% of M2 cases, 33.3 
of  M3  and  20%  of  M5;  but  M4  patients  lacked  this 
marker.  (Table  1)  The  CBC  analysis  demonstrated  a 
wide range of haemoglobin concentration, Platelet and 
WBC  count  which  varied  from  normal  to  anaemia, 
thrombocytopenia to thrombocytosis and leukopenia to 
hyper  leukocytosis.  The  status  of  remission  and 
aberrant marker was illustrated in Table 2. 
 
Table 1. Frequency of lymphoid marker in subclass of AML 
patient in FAB study 
FAB 
T CELL MARKER  B CELL MARKER 
CD2  CD3  CD7  CD10  CD19  CD20  CD22 
M0  1  1  1  1  1  2  3 
M1  7  5  8  2  3  0  2 
M2  3  1  4  0  1  0  0 
M3  3  0  0  0  0  0  1 
M4  0  0  0  0  0  0  0 
M5  1  1  1  0  0  1  0 
M7  0  0  1  0  1  1  0 
 
 
Table 2. Aberrant marker and remission statues 
Positive aberrant 
marker 
Remission status 
Remission  Not Remission  Total 
CD2  5  10  15 
CD3  3  5  8 
CD7  6  10  16 
CD10  0  3  3 
CD19  1  5  6 
CD20  1  2  3 
CD22  1  5  6 
 
Descriptive  statistics  for  the  variables  of  acute 
myelogenous leukemia. 
The WBC ranged from (430 - 2x105/µL) with a median 
of  8500/µL.  The  median  and  range  for  haemoglobin 
was  8gm/dl  (5.2  –  14gm/dl),  and  the  platelet  count 
range was from (3600 – 8.8x104/µL) with a median of 
3.95x105/µL. (Table 3) 
 
Tabel 3. Patient characteristics in this study 
Characteristics  Range  Number 
 
AGE 
≤30  17( 30.4%) 
31-40  14(25%) 
41-50  7(12.5%) 
51≤  18(32.1%) 
Hb 
<10  39(69.6%) 
10≤  17(30.4%) 
WBC 
<10000  34(60.7%) 
10000≤  22(39.3%) 
PLT 
<20000  13(23.2%) 
20000≤  43(76.8%) 
Bone marrow Blast 
<70%  55(98.2%) 
70%≤  1(1.8%) 
 
Discussion 
Human  acute  leukemias  are  broadly  described  by 
differentiation  into  myeloid  or  lymphoid  lineages 
according  to  the  expression  of  surface  and/or 
cytoplasmic  markers  associated  with  their  normal 
myeloid  or  B-cell  and  T-cell  counterparts.
15 
Immunophenotyping is a convenient method for quick  
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and  reproducible  diagnosis  of  the  majority  of 
hematological  malignancies.
16  Aberrant  phenotype  in 
AML is known as a poor prognostic indicator.
17 
In the present study 56 new cases of AML for aberrant 
expression of lymphoid antigens were investigated. The 
presence  of  aberrant  markers  more  than  20%, 
considered  as  cut-off  value  for  aberrant  phenotype 
definition. In the under study group, the ratio of male to 
female equals 1.5 to 1.0, which is similar with other 
ratio  reported  from  international  study.
18  Although, 
most  prior  studies  emphasize  that  AML  is  more 
prevalent  in  patients  over  60  years  old  in  general 
populations,
19  our  finding  shows  two  age  peak 
incidence for AML (≤30 and 51≤ years old). 
Most  frequently  expressed  lymphoid  antigens  were 
CD7  (31%)  and  CD2  (29%);  and  other  marker  was 
expressed  as:  CD3  (15.7%),  CD19  (12.2%)  CD22 
(12.2%), CD20 (6.1%). This finding is in contrast with 
El-Sissy et al that they showed that CD9 (29.4%) has 
highest  frequency  in  AML  cases.
15  In  another  study, 
Bharat  Bhushan  et  al  noteded  that  the  frequency  of 
CD7  expression  was  lower  than  CD19  expression  in 
AML.
20  These  findings  of  the  current  study  are 
consistent with those of Bahia, Shen and John et al who 
found  CD7  was  the  most  frequent  lymphoid  antigen 
expressed in AML.
11,21,22 In this research, FAB studies 
on AML patient showed that AML-M2 was the most 
common subtype of AML, which is in agreement with 
Lowenberg  H  findings.
19  Another  important  finding 
was that CD7 aberrant phenotype includes incidence in 
M1 (72.7 %) and in M2 (28.5), which in contrast with 
Bharat  Bhushan  who  noted  that  CD7  had  high 
occurrence in M5.
20 It has been investigated that CD2 
is  the  most  commonly  expressed  lymphoid  antigen 
followed by CD7, however the previous study focuses 
on CD19 expression following CD7
20 and El-Sissy et al 
noted  CD7  is  afterward  respect  to  CD9.
15  Recently, 
aberrant phenotype has been used to stage and monitor 
minimal  residual  disease  (MRD)  in  acute  myeloid 
leukemia.
23  This  experiment  did  not  detect  any 
significant  correlation  between  aberrant  phenotypes 
and  MRD  in  leukemic  patients.  Even  though  prior 
research  demonstrate  that  the  aberrant  phenotype 
cannot be used as criterion to predict the relapse and 
remission of leukemia,
24 A strong relationship between 
aberrant  phenotype  and  MRD  has  been  noted  in  the 
literature.
25 
 
Conclusion 
Our findings showed that CD7 and CD2 were the most 
common aberrant marker in Iranian patients with AML. 
However,  we  are  not  find  any  significant  correlation 
between aberrant phenotype changing and MRD in our 
population.  Taken  together,  this  findings  help  to 
provide  new  insights  in  to  the  investigation  of  other 
aberrant  phenotypes  that  may  play  roles  in  diagnosis 
and therapeutic of AML. 
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